A blend nickname is not identity. Identity is the component list, the CAS or sequence for each line, the masses, and the lot number on both the vial and the certificate of analysis. If those fields do not match, the letters on the storefront do not matter. This is a decoder, not a catalog of …
Tesamorelin and CJC-1295 (no DAC) are GHRH-axis ligands. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. None of them is a GLP-1, GIP, or glucagon receptor agonist. Semaglutide, tirzepatide, and retatrutide live in the incretin / glucagon GPCR family. Mixing those catalogs under one “peptide” heading is convenient. It is also how a methods section names the …
Semaglutide is a peptide. Orforglipron is not. FDA approved Foundayo (orforglipron) on 1 April 2026 as a small-molecule, non-peptide, oral GLP-1 receptor agonist. Same receptor family as peptide GLP-1R agonists. Different chemical class. A research peptide labeled “semaglutide” is not an orforglipron lot, and an orforglipron tablet is not a peptide reagent. That class split …
GLOW, KLOW, and Wolverine are catalog objects. They are nicknames for multi-component blends. They are not the titles of peer-reviewed combination studies. Papers exist on individual components. A paper on BPC-157 is not a GLOW study. A paper on GHK-Cu is not a KLOW study. A paper on thymosin β4-related peptides is not a Wolverine …
Ozempic, Wegovy, and Rybelsus contain semaglutide base, not a salt. Mounjaro and Zepbound contain tirzepatide base, not a salt. A salt form (acetate, sodium, or any other counter-ion listed on a COA) is a different active ingredient than the component of those approved drugs. That is an identity statement. It is the statement FDA has …
A research-use-only (RUO) peptide reagent is not active pharmaceutical ingredient for 503A compounding. Those are two different objects: a laboratory chemical sold with a research intended use, and a bulk drug substance that a licensed pharmacy may use, when compounding is allowed at all, under the Federal Food, Drug, and Cosmetic Act. That distinction is …
There is no GLP-3 receptor. Retatrutide (LY3437943) is a single-chain agonist at three named receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). The third arm is glucagon, not a third glucagon-like peptide. That sentence is the whole correction. Catalogs still print “GLP-3” because it is short …
Before most people searched “retatrutide,” the molecule had a code on an Eli Lilly badge: LY3437943. In 2022, Tamer Coskun and colleagues at Lilly published that peptide in Cell Metabolism as a single-chain agonist built to engage three receptors at once: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 …
A lyophilized peptide looks like it should ignore the weather. It is a dry cake in a sealed vial, not a solution sloshing in a tube. So the obvious question is fair: if freeze-drying already pulled most of the water out, why does anyone put cold packs in the box? The short answer is that …